NYSEAMERICAN:TRXC

TransEnterix Stock Forecast, Price & News

$1.52
-0.22 (-12.64 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.48
Now: $1.52
$1.78
50-Day Range
$0.41
MA: $0.53
$1.17
52-Week Range
$0.28
Now: $1.52
$6.95
Volume13.33 million shs
Average Volume44.56 million shs
Market Capitalization$217.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
TransEnterix logo

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.53 million
Cash Flow$1.09 per share
Book Value$2.68 per share

Profitability

Net Income$-154,200,000.00
Net Margins-2,149.15%

Miscellaneous

Market Cap$217.02 million
Next Earnings DateN/A
OptionableOptionable

Headlines

See More Headlines

MarketRank

Overall MarketRank

0.71 out of 5 stars

Medical Sector

1265th out of 2,025 stocks

Surgical & Medical Instruments Industry

114th out of 169 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
$1.52
-0.22 (-12.64 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Is TransEnterix a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TransEnterix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRXC, but not buy additional shares or sell existing shares.
View analyst ratings for TransEnterix
or view top-rated stocks.

What stocks does MarketBeat like better than TransEnterix?

Wall Street analysts have given TransEnterix a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TransEnterix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) announced its quarterly earnings results on Thursday, November, 5th. The medical instruments supplier reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.11. The medical instruments supplier had revenue of $0.81 million for the quarter, compared to analysts' expectations of $0.73 million. TransEnterix had a negative trailing twelve-month return on equity of 83.74% and a negative net margin of 2,149.15%.
View TransEnterix's earnings history
.

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), Actinium Pharmaceuticals (ATNM), XOMA (XOMA), Geron (GERN), OPKO Health (OPK), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $1.52.

How much money does TransEnterix make?

TransEnterix has a market capitalization of $217.02 million and generates $8.53 million in revenue each year. The medical instruments supplier earns $-154,200,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

Where are TransEnterix's headquarters?

TransEnterix is headquartered at 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.